Elicera Therapeutics
Elicera Therapeutics receives additional subscription commitments from the board and management in the ongoing rights issue
On 20 February 2024 the extraordinary general meeting of the Company resolved on a rights issue of units of approximately SEK 64 million (the “Rights Issue”). The subscription period in the Rights Issue started on 23 February 2024 and ends 8 March 2024. Elicera has received additional subscription commitments from the following members of the board and management who intend to subscribe in the Rights Issue:
| Shareholder | Role in the Company | Initial commitment, SEK | Increased commitment, SEK |
| Jamal El-Mosleh | CEO | 250,000 | 100,000 |
| Di Yu | Head of Translational Research and co-fonder | 100,000 | 100,000 |
| Jan Zetterberg | Board member | 0 | 230,000 |
| Total | 350,000 | 430,000 |
Through these subscription commitments, the board and management demonstrate their continued confidence in Elicera’s future prospects. Overall the subscription commitments from the board and management amount to approximately 1 million SEK.
| Datum | 2024-03-04, kl 14:00 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!